인노비아(INVA) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 인노비아(INVA)?

인노비아(INVA) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of INVA?

The market cap of INVA is approximately $1.6B, ranking 2,302 within its sector.

Q: What is the P/E ratio of INVA?

INVA has a P/E ratio of approximately 3.5x, which can be used to assess its valuation relative to the Healthcare sector average.

Q: What is the 52-week high and low for INVA?

INVA has recorded a 52-week high of $25.15 and a low of $16.52.

INVA

Innoviva Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$21.30

-0.14 ▼ -0.65%

🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)

$21.30

+0.00 +0.00%

인노비아(INVA) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$1.6B

스몰캡

P/E

3.5

저평가 구간

배당수익률

없음

52주 위치

55%

저점 +29% · 고점 -15%

애널리스트

매수

C+

Fundamental health

vs. Biotechnology 소형주

수익성

Top 10%

성장

Top 65%

밸류에이션

Top 84%

재무 안정

Top 24%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 5년 (not other companies).

💎 Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 3원. Over the past 5년, it usually traded around 5원. One of the cheapest stretches of the past 5년.

Pricy doesn't mean bad — it means expectations are already baked in.

Index ⓘ	RUT	P/E ⓘ	3.54	EPS (ttm) ⓘ	6.01	Insider Own ⓘ	1.25%	Shs Outstand ⓘ	73.8M	Perf Week ⓘ	0.09%
Market Cap ⓘ	1.57B	Forward P/E ⓘ	9.51	EPS next Y ⓘ	-37.22%	Insider Trans ⓘ	-	Shs Float ⓘ	72.9M	Perf Month ⓘ	-8.78%
Enterprise Value ⓘ	1.29B	PEG ⓘ	-	EPS next Q ⓘ	0.44	Inst Own ⓘ	103.75%	Short Float ⓘ	9.63%	Perf Quarter ⓘ	-9.63%
Income ⓘ	0.50B	P/S ⓘ	3.62	EPS this Y ⓘ	8.12%	Inst Trans ⓘ	-0.78%	Short Ratio ⓘ	8.38	Perf Half Y ⓘ	8.9%
Sales ⓘ	0.43B	P/B ⓘ	1.17	EPS next 5Y ⓘ	-14.67%	ROA ⓘ	32.63%	Short Interest ⓘ	7.02M	Perf YTD ⓘ	6.55%
Book/sh ⓘ	18.18	P/C ⓘ	2.57	EPS past 3/5Y ⓘ	- 10.35%	ROE ⓘ	50.72%	52W High ⓘ	-15.29% ($25.15)	Perf Year ⓘ	13.78%
Cash/sh ⓘ	8.29	P/FCF ⓘ	8.64	Sales past 3/5Y ⓘ	325.77% 3.93%	ROIC ⓘ	30.24%	52W Low ⓘ	28.93% ($16.52)	Perf 3Y ⓘ	64.1%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	6.43	EPS Y/Y TTM ⓘ	836.84%	Gross Margin ⓘ	71.36%	Volatility(W/M) ⓘ	2.08% 2.52%	Perf 5Y ⓘ	60.63%
Dividend TTM ⓘ	-	EV/Sales ⓘ	2.97	Sales Y/Y TTM ⓘ	13.25%	Oper. Margin ⓘ	36.93%	ATR (14) ⓘ	0.55	Perf 10Y ⓘ	80.66%
Dividend Ex-Date ⓘ	2015/9/8	Quick Ratio ⓘ	20.07	EPS Q/Q ⓘ	398.24%	Profit Margin ⓘ	116.08%	RSI (14) ⓘ	40.75	Recom ⓘ	2
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	21.13	Sales Q/Q ⓘ	10.17%	SMA20 ⓘ	-2.96% ($21.95)	Beta ⓘ	0.35	Target Price ⓘ	$35.5
Payout ⓘ	-	Debt/Eq ⓘ	0.25	Earnings ⓘ	2026/5/6	SMA50 ⓘ	-4.19% ($22.23)	Rel Volume ⓘ	0.75	Prev Close ⓘ	$21.44
Employees ⓘ	159	LT Debt/Eq ⓘ	0.24	EPS/Sales Surpr. ⓘ	469.23% -3.52%	SMA200 ⓘ	-0.66% ($21.44)	Avg Volume(3M) ⓘ	0.84M	Price ⓘ	$21.3
IPO ⓘ	2004/10/5	Option/Short ⓘ	Yes/Yes			Trades ⓘ	8648	Volume ⓘ	624,274	Change ⓘ	-0.65%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $98M (YoY +11%) · 순이익 $187M (YoY +501%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Innoviva Inc (INVA) Investment Analysis

What kind of company is Innoviva Inc?

인노비아(INVA) 가치주

Healthcare · Biotechnology

Healthcare Stocks

A US healthcare company that combines pharmaceutical royalties with a specialty pharmaceuticals business. It generates royalty income from respiratory therapeutics and other products, while also operating acquired specialty pharmaceutical and infectious disease treatment businesses, running a model that combines stable royalty cash flows with specialty pharmaceuticals. The company has established itself as a healthcare operator spanning both royalties and specialty pharmaceuticals.

Learn more about Innoviva Inc →

Market Cap

$1.6B

Approx. KRW 2.2 trillion

⚖️ 1% of Samsung Electronics

Market Cap Rank2302

Employees159people

IPO2004/10/05

Current Price$21.30 ≈ 29,181원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 6일 (수) · 장 마감 후 EPS +469.2% 매출 -3.5%

🔔 Earnings release 2026년 2월 25일 (수) · 장 마감 후 EPS +252.1% 매출 +11.7%

🎯 Ex-div 2015년 9월 8일 (화)

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

36.9%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 소형주 Median -210.9% · Top tier

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

116.1%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 소형주 Median -187.6% · Top tier

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

71.4%

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology 소형주 Median 84.9% · Bottom 39%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

50.7%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -37.5% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

32.6%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -21.8% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

30.2%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -25.0% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.25

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

21.13

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

20.07

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$35.50

현재가 대비 +66.7%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

9.51배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

-37.2%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

-14.7%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability

Beat estimates in 2 of the last 2 quarters

예상 상회

예상 부합

예상 하회

100%

상회 비율

+10.0%

평균 서프라이즈

2026.05.06

상회

실적 $0.47 · 예상 $0.43 +8.8%

2026.02.25

상회

실적 $0.47 · 예상 $0.42 +11.1%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Concerns

Growth is lagging the industry average

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+8.1%

양호

My positionMid-range

Low range Average High range

가치주 소형주 Median 4.4% · Top 44%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

-37.2%

매우 부진

My positionBottom 5%

Low range Average High range

가치주 소형주 Median 8.6% · Bottom tier

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

-14.7%

부진

My positionBottom 25%

Low range Average High range

가치주 소형주 Median 3.7% · Bottom 14%

📊 How much has it grown? (actual results)

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+10.3%

평균

My positionMid-range

Low range Average High range

가치주 소형주 Median 10.6% · Bottom 49%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+3.9%

부진

My positionBottom 25%

Low range Average High range

가치주 소형주 Median 12.0% · Bottom 24%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+10.2%

양호

My positionMid-range

Low range Average High range

가치주 소형주 Median 4.2% · Top 36%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Underperformed the market by 8%p over 5 years

INVA +60.6% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-7.7%p

slightly behind the market

vs Health Care (XLV)

+36.1%p

well ahead of the sector average

1-year basis

vs S&P 500

-2.2%p

roughly in line with the market

vs Health Care (XLV)

-5.9%p

slightly behind the sector average

Rank among peers

5-year return Top among peers Based on 123 peers

1-year return Lower-Mid (lower 33%) Based on 154 peers

Current position within 52-week range

Low (-28.9%p) High (-15.3%p)

Current price is 28.9% above the 52-week low and 15.3% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-12.5%

Annualized volatility

25.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $21.30 below the midline ($21.95). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.327 < Signal -0.251 in negative zone + Hist negative (-0.076). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 40.8 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 14.9.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

3.54x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 소형주 median 7.65x · Top 14% — relatively cheap within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

9.51x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 소형주 median 18.33x · Top 21% — relatively cheap within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

1.17x

✓ Very cheap

My positionTop 5%

Low range Average High range

Biotechnology 소형주 median 3.34x · Top 1% — relatively cheap within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

3.62x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 소형주 median 14.61x · Top 17% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

6.43x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 소형주 median 19.26x · Top 18% — relatively cheap within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

8.64x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 소형주 median 14.14x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$35.50 vs. current price +66.7%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership flow shows some pressure

Institutional modest net selling -0.8% · Short interest moderate 9.6% · Short interest up +0.5pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

-0.8%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 103.8%

Institution-led, stable structure

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 1.3%

Typical level

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 0.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

9.6%

Moderate

Healthcare 소형주 Median 11.2%

Past 90 days 📈 +0.5%p increase

Short interest days to cover

8.4 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 73.8M주

Float (tradable shares) 72.9M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding INVA

ETFs with the highest weightings · 10 total shown

PJP

Invesco Pharmaceuticals ETF

2.88%

$454M

SIXS

ETC 6 Meridian Small Cap Equity ETF

2.33%

$140M

XPH

State Street SPDR S&P Pharmaceuticals ETF

1.99%

$475M

PILL

Direxion Daily Pharmaceutical & Medical Bull 3X ETF

1.37%

$21M

SCOW

Pacer S&P SmallCap 600 Quality FCF Aristocrats ETF

1.27%

$2M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
INVA This Stock	$1.6B	3.5 ▲	1.2 ▲	50.72% ▲	-	-0.7%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 인노비아(INVA)?

인노비아(INVA) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of INVA?

The market cap of INVA is approximately $1.6B, ranking 2,302 within its sector.

What is the P/E ratio of INVA?

INVA has a P/E ratio of approximately 3.5x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for INVA?

INVA has recorded a 52-week high of $25.15 and a low of $16.52.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.